The Interfaith Center on Corporate Responsibility, submitted shareholder proposals at the annual meetings of Abbvie, Amgen, Biogen, Bristol Myers Squibb and Eli Lilly Co. to demand compiled reports about the risks of high drug prices, while also examining the connection between pricing strategies and executive compensation, reports STAT.
“In our view, excessive dependence on drug price increases is a risky and unsustainable strategy, especially when price hikes drive large senior executive payouts,” one shareholder resolution stated, according to STAT.
By pushing companies to reveal the links between prices and pay, the coalition hopes drugmakers will take more personal responsibility for the increasing drug prices.
More articles on supply chain:
4 latest FDA approvals
Study: 95.7% of US pharma sales go through primary distributors
10 recent pharma layoffs
